Venezuela Medical Device Regulation 2024–2026: Key Changes and Forward Outlook

1. Key takeaways

Between 2024 and 2026 the Venezuelan regulatory framework for medical devices produced 6 key changes, a density markedly higher than in the preceding decade. The common direction of this round is to use the tariff code as the pivot and embed health approval into the digital flows of foreign trade and customs.

The judgement for manufacturers is this: the reform is not finished. The three changes already in place, namely the new tariff schedule, the platform migration and the tightening of import requirements, are the earlier and later segments of a single reform, and further instruments on implementing rules, data standards and enforcement practice are still probable. Project planning should assume that the rules will keep changing, not that they have stabilized.

This assumption has a concrete budgeting consequence. A plan that treats the current framework as final prices regulatory work as a one-off cost; a plan that treats it as provisional prices monitoring, re-classification and document refresh as recurring costs. The second is closer to what the record of the past two years supports, and it is also cheaper than discovering the difference during a clearance hold.

2. Legal basis

Item 8 in the table above is a United States extraterritorial rule and differs in nature from the preceding seven; it is listed because of its material effect on payment channels.

3. Expert insights

1. The position of the three differentiating levers is clear in this round. The COMEX platform mandate (items 5 and 6) changes the entry point; the new tariff schedule (items 1 and 3) changes classification and the legal regime; the sanctions adjustment (item 8) changes the payment environment. Each acts at the front end, the upstream layer and the periphery of the process respectively, and together they define the complete set of constraints on a Venezuelan project today. A project plan that addresses only one of the three will be correct and still unexecutable.

2. The form of publication deserves attention: decrees and circulars dominate, and the statutes were not amended. Of the eight changes, none originates in an amendment to the health organization law of 1998 or the medicines law of 2000. This confirms the judgement in article 10 of this series: stable statute law combined with high-frequency circular activity is a basic characteristic of the Venezuelan regulatory system. The practical implication is that monitoring the statutes is close to useless, while monitoring the Gaceta Oficial and the SACS circular stream is essential.

3. Effective dates are not synchronized, and transitional arrangements differ as well. Decreto N° 4.944 allowed a 30-day legal gap; Circular DGSACS/0002/2025 took effect the same day; Decreto N° 5.146 remains valid for 1 year. Because the timing design differs from instrument to instrument, no single rule can be used to predict it. Each instrument has to be read for its own commencement provision, and instruments with a defined life have to be diarized for expiry from the day they are published.

4. Outlook beyond 2026: three probable directions. First, implementing rules and operating guidance for the COMEX platform are likely to follow, further specifying the procedures each directorate performs on it. Second, as integration of the three data ends advances, requirements on data consistency at entry are likely to tighten, making classification and certificate accuracy more critical. Third, tariff and tax relief instruments carry defined validity, such as the 1-year term of Decreto N° 5.146, and their renewal or adjustment after expiry has to be tracked period by period. All three are inferences from the structure of published instruments and do not constitute a forecast of specific rules.

4. Practical recommendations

1. Regulatory affairs leads: maintain a regulatory change ledger organized in four tiers (law, regulation, resolution or decree, circular), recording the number, date, effective date and status of each entry.
2. Regulatory operations: monitor at a frequency of no less than once a week, and set pre-expiry review reminders for every time-limited instrument such as the 1-year relief decree.
3. Project managers: plan on the assumption that the rules will keep changing, and reserve adjustment capacity in both schedule and budget.
4. Manufacturers: agree notification duties and deadlines for regulatory changes in the authorized representative agreement, so that information reaches the manufacturer without delay.
5. License holders: run a full quarterly review, updating the verification date and re-checking the consistency of classification, certificates and labels.

5. Verification checklist

• □ A regulatory change ledger exists and covers the four document tiers and the eight changes
• □ Monitoring frequency is set at no less than once a week
• □ Pre-expiry review reminders are configured for time-limited instruments such as the 1-year relief decree
• □ Schedule and budget reserve capacity for rule adjustments
• □ Notification duties and deadlines for the authorized representative are set out in the agreement
• □ A quarterly full review mechanism exists, with this verification dated October 29, 2026

Regulatory information verified as of October 29, 2026

All conclusions published here defer to the current regulatory texts as issued by the competent authority, verified item by item before delivery.

— GRZAN Regulatory Team

GRZAN supports medical device and IVD manufacturers, importers and authorized representatives with registration and post-market compliance in Venezuela: dossier preparation and filing through the SACS and COMEX channels, license-holder coordination, technovigilance and adverse event workflows, recall and field corrective action planning, inspection readiness, and continuous monitoring of circulares and decrees. For tailored support on your Venezuela portfolio, contact the GRZAN regulatory team at info@grzanglobal.com.